Frequency Therapeutics Inc. Common Stock (NASDAQ: FREQ)
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business prospects. Specifically, the Complaint alleges that during the Class Period, Defendants misled investors about the Phase 2a study of FX-322.